ODAC Approves MRD End Point in Multiple Myeloma Trials
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers
LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.
Olutasidenib Yields Enduring Remissions in Previously Treated IDH1+ AML
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.
Microwave Ablation Shows Noninferiority to Surgery in Thyroid Cancer
Microwave ablation may be a go-to treatment option instead of surgery for patients with multifocal T1N0M0 papillary thyroid cancer.
Real-World Data Support SLNB Omission in HR+ HER2– Breast Cancer
Oncologic outcomes from a real-world analysis appear to be comparable with those observed in the sentinel lymph node biopsy arm of the SOUND trial.
Time to Screening/Treatment/Surgery is Underestimated at Breast Centers
The National Accreditation Program for Breast Centers looked at time intervals to see where delays occurred throughout the process for those with breast cancer.
Diagnostic Delays in Younger Women With Breast Cancer Are Mostly Patient-Related
Young patients with breast cancer were more likely to be the reason for diagnostic delays vs system delays, partly due to less concern for their symptoms.
Rintatolimod Combo Yields Clinical Benefit in Recurrent Ovarian Cancer
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.
Toripalimab Combo Receives Chinese Approval for Advanced RCC
Toripalimab plus axitinib is now an approved regimen in China for patients with medium- to high-risk unresectable or metastatic renal cell carcinoma.
Data Show Improved Posttransplant Outcomes in Elderly AML Population
Real-world data may serve as a benchmark for future studies in elderly patients with acute myeloid leukemia.
FDA Grants Fast Track Designation to Tamibarotene in Newly Diagnosed AML
Findings from SELECT-AML-1 support the potential benefit of tamibarotene in those with acute myeloid leukemia harboring RARA gene overexpression.
Linvoseltamab Shows Responses, Safety in Relapsed/Refractory Myeloma
Investigators also look to assess linvoseltamab in relapsed/refractory multiple myeloma as part of the phase 3 LINKER-MM3 trial.
Rectal Cancer Surgical Outcomes Improved at Accredited Hospitals
In-hospital mortality and complication rates were lower at accredited hospitals vs those not accredited for patients undergoing rectal cancer surgery.
AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma
First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.
Sunvozertinib Earns FDA Breakthrough Therapy Designation in EGFR+ NSCLC
The phase 1/2 WU-KONG1 findings support the breakthrough therapy designation for sunvozertinib for those with EGFR-mutated non–small cell lung cancer.
Adagrasib Combo Yields Encouraging Responses in KRAS G12C–Mutated CRC
Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.
PROACTIVE Trial to Use Neoadjuvant Approach in Unresectable Pancreatic Adenocarcinoma
The pilot trial is planning to enroll 20 patients who are deemed inoperable but do not have metastatic disease.
miRNA Assay May Lead to Early Detection in PDAC
The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.
Saruparib Shows Favorable Activity, Safety in Mutant Advanced Solid Tumors
Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.
MRD Negativity Status Following Surgery Confers Survival in MIBC
Patients with muscle-invasive bladder cancer who remain molecular residual disease negative following cystectomy may be spared from adjuvant therapy.
Combatting Cancer Surgery Disparities Due to Racial-Economic Segregation
Retrospective findings may establish a “framework” for improving the accessibility, timeliness, and appropriateness of surgical cancer care in disadvantaged areas.
Finding Ways to Break the Mold in GU Oncology
Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
Optimizing Neoadjuvant Therapy Efficacy in dMMR Gastroesophageal Cancer
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Blood-Based Test May Help Detect CRC in Average-Risk Population
The PREEMPT trial analyzed samples from 27,010 average-risk adults to determine the specificity of detecting colorectal cancer.
Predicting Neoadjuvant Immunotherapy Responses in Gastroesophageal Cancer
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
China Accepts sNDA for Savolitinib in Previously Treated MET Exon 14 NSCLC
Data from a phase 3b trial support a supplemental new drug application in China for savolitinib in previously treated non–small cell lung cancer with MET exon 14 alterations.
Tislelizumab Shows Improvements in Efficacy Vs Chemo in Esophageal Cancer
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.
Durvalumab Significantly Improves Survival in Limited-Stage SCLC
Treatment with durvalumab raises no new safety signals among patients with limited-stage small cell lung cancer in the phase 3 ADRIATIC trial.
Ribociclib Combo Improves iDFS in HR+/HER2– Early Breast Cancer
Data from the NATALEE trial show that ribociclib may benefit a broad population of patients with early breast cancer who have an increased risk of recurrent disease.